Biogen Inc header image

Biogen Inc

BIIB

Equity

ISIN null / Valor 1720684

NASDAQ (2026-09-29)
USD 227.07-0.71%

Biogen Inc
UMushroom community rating:

star star star star star
4.40 5 votes No rating yet
NegativeNeutralPositive

About company

Biogen Inc is a prominent biotechnology company that focuses on developing therapies for a range of complex and debilitating diseases. Established in 1978, the company has made significant advancements in the field, particularly in neurology, neuropsychiatry, specialized immunology, and rare diseases. Biogen is known for its innovative treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The company is dedicated to serving humanity through scientific research and is committed to creating a healthier, more sustainable, and equitable world.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

63.9%1Y
-11.6%3Y
-20.5%5Y

Performance

34.9%1Y
30.8%3Y
33.3%5Y

Volatility

Market cap

33551 M

Market cap (USD)

Daily traded volume (Shares)

1,161,174

Daily traded volume (Shares)

1 day high/low

151.14 / 148.23

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.40

5 votes
Performance:
starstarstarstarstar
4.20
Innovation:
starstarstarstarstar
4.80
Society:
starstarstarstarstar
4.20
Nature:
starstarstarstarstar
4.00
Tonia Zimmermann
Switzerland, 13 Jun 2023
star star star star star
Not just leading in supporting Alzheimer patience, but also pioneering in digital health.
Igor Jovicic
Switzerland, 13 Jun 2023
star star star star star
A company that seems to be making an impact in the biotech sector!
Luba Schoenig
Switzerland, 13 Jun 2023
star star star star star
FDA Advisory Committee recommended the Food and Drug Administration to approve Leqembi, an Alzheimer's drug from Biogen and its Japanese partner Eisai.

EQUITIES OF THE SAME SECTOR

MEDICLIN AG
MEDICLIN AG MEDICLIN AG Valor: 1158721
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.85%EUR 5.30
MPH Health Care AG
MPH Health Care AG MPH Health Care AG Valor: 57233620
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.41%EUR 27.30
2invest AG
2invest AG 2invest AG Valor: 110098281
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.25%EUR 7.96
The Platform Group AG
The Platform Group AG The Platform Group AG Valor: 57796644
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.31%EUR 1.00
Maternus-Kliniken AG
Maternus-Kliniken AG Maternus-Kliniken AG Valor: 335800
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.19%EUR 0.91
aap Implantate AG
aap Implantate AG aap Implantate AG Valor: 57872565
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.80%EUR 1.64
Lifco Ab
Lifco Ab Lifco Ab Valor: 111355378
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.19%SEK 316.60
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB Valor: 2676862
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.64%SEK 436.60
Elekta AB
Elekta AB Elekta AB Valor: 613625
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.10%SEK 52.60
Essity AB
Essity AB Essity AB Valor: 36846754
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.19%SEK 259.50